{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T05:10:29Z","timestamp":1762492229343,"version":"build-2065373602"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T00:00:00Z","timestamp":1592438400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008321","name":"Pennsylvania State University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000761","name":"Imperial College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000761","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000779","name":"University of London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000779","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008349","name":"Universit\u00e4t Duisburg-Essen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["IJC Heart & Vasculature"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.ijcha.2020.100573","type":"journal-article","created":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T23:53:43Z","timestamp":1594338823000},"page":"100573","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Assessment of OMT-28, a synthetic analog of omega-3 epoxyeicosanoids, in patients with persistent atrial fibrillation: Rationale and design of the PROMISE-AF phase II study"],"prefix":"10.1016","volume":"29","author":[{"given":"Sarah","family":"Berlin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Goette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciana","family":"Summo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janine","family":"Lossie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Gebauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naab","family":"Al-Saady","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo","family":"Calo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald","family":"Naccarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolf-Hagen","family":"Schunck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.John","family":"Camm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dobromir","family":"Dobrev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ijcha.2020.100573_b0005","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.113.005119","article-title":"Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study","volume":"129","author":"Chugh","year":"2014","journal-title":"Circulation"},{"issue":"9989","key":"10.1016\/j.ijcha.2020.100573_b0010","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0140-6736(14)61774-8","article-title":"50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study","volume":"386","author":"Schnabel","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ijcha.2020.100573_b0015","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1161\/CIRCULATIONAHA.106.177292","article-title":"ACC\/AHA\/ESC 2006 guidelines for the management of patients with atrial fibrillation","volume":"114","author":"Fuster","year":"2006","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.ijcha.2020.100573_b0020","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1161\/CIRCULATIONAHA.116.023163","article-title":"Modifiable risk factors and atrial fibrillation","volume":"136","author":"Lau","year":"2017","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.ijcha.2020.100573_b0025","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1161\/CIRCRESAHA.114.303211","article-title":"The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms","volume":"114","author":"Andrade","year":"2014","journal-title":"Circ. Res."},{"issue":"1","key":"10.1016\/j.ijcha.2020.100573_b0030","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1016\/j.hrthm.2016.05.028","article-title":"EHRA\/HRS\/APHRS\/SOLAECE expert consensus on atrial cardiomyopathies: Definition, characterization, and clinical implication","volume":"14","author":"Goette","year":"2017","journal-title":"Heart Rhythm"},{"issue":"6","key":"10.1016\/j.ijcha.2020.100573_b0035","first-page":"608","article-title":"Rapid pacing of embryoid bodies impairs mitochondrial ATP synthesis by a calcium-dependent mechanism - a model of in vitro differentiated cardiomyocytes to study molecular effects of tachycardia","volume":"1762","author":"Schild","year":"2006","journal-title":"BBA"},{"issue":"5","key":"10.1016\/j.ijcha.2020.100573_b0040","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3181\/0706-RM-155","article-title":"Mitochondrial dysfunction and redox signaling in atrial tachyarrhythmia","volume":"233","author":"Bukowska","year":"2008","journal-title":"Exp. Biol. Med. (Maywood)"},{"issue":"9","key":"10.1016\/j.ijcha.2020.100573_b0045","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCRESAHA.114.302226","article-title":"Cellular and molecular electrophysiology of atrial fibrillation initiation, maintenance, and progression","volume":"114","author":"Heijman","year":"2014","journal-title":"Circ. Res."},{"issue":"2","key":"10.1016\/j.ijcha.2020.100573_b0050","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","volume":"140","author":"January","year":"2019","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ijcha.2020.100573_b0055","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/eurheartj\/ehw260","article-title":"Catheter ablation in patients with persistent atrial fibrillation","volume":"38","author":"Kirchhof","year":"2017","journal-title":"Eur. Heart J."},{"issue":"8","key":"10.1016\/j.ijcha.2020.100573_b0060","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1080\/13543784.2017.1353601","article-title":"Investigational antiarrhythmic agents: promising drugs in early clinical development","volume":"26","author":"Heijman","year":"2017","journal-title":"Expert Opin. Invest. Drugs"},{"issue":"2","key":"10.1016\/j.ijcha.2020.100573_b0065","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1001\/jama.2018.8102","article-title":"Effect of a home-based wearable continuous ECG monitoring patch on detection of undiagnosed atrial fibrillation: the mSToPS randomized clinical trial","volume":"320","author":"Steinhubl","year":"2018","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ijcha.2020.100573_b0070","doi-asserted-by":"crossref","first-page":"48","DOI":"10.15420\/aer.2011.3.1.48","article-title":"The role of continuous monitoring in atrial fibrillation management","volume":"3","author":"Camm","year":"2014","journal-title":"Arrhythmia Electrophysiol. Rev."},{"issue":"20","key":"10.1016\/j.ijcha.2020.100573_b0075","doi-asserted-by":"crossref","first-page":"e623","DOI":"10.1161\/CIR.0000000000000568","article-title":"Atrial fibrillation burden: moving beyond atrial fibrillation as a binary entity: a scientific statement from the American Heart Association","volume":"137","author":"Chen","year":"2018","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.ijcha.2020.100573_b0080","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.tcm.2016.03.014","article-title":"Amiodarone and dronedarone: An update","volume":"26","author":"Vamos","year":"2016","journal-title":"Trends Cardiovasc. Med."},{"key":"10.1016\/j.ijcha.2020.100573_b0085","doi-asserted-by":"crossref","DOI":"10.1093\/europace\/euz193","article-title":"Safety and efficacy of dronedarone from clinical trials to real-world evidence: implications for its use in atrial fibrillation","author":"Boriani","year":"2019","journal-title":"Europace"},{"key":"10.1016\/j.ijcha.2020.100573_b0090","doi-asserted-by":"crossref","unstructured":"L. Valembois, E. Audureau, A. Takeda, W. Jarzebowski, J. Belmin, C. Lafuente-Lafuente, Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation, Cochrane Database Syst. Rev. 9 (2019) CD005049.","DOI":"10.1002\/14651858.CD005049.pub5"},{"issue":"5","key":"10.1016\/j.ijcha.2020.100573_b0095","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCRESAHA.117.311081","article-title":"Translational challenges in atrial fibrillation","volume":"122","author":"Heijman","year":"2018","journal-title":"Circ. Res."},{"key":"10.1016\/j.ijcha.2020.100573_b0100","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.3389\/fphys.2018.01380","article-title":"Calcium in the pathophysiology of atrial fibrillation and heart failure","volume":"9","author":"Denham","year":"2018","journal-title":"Front. Physiol."},{"key":"10.1016\/j.ijcha.2020.100573_b0105","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.3389\/fphys.2018.01383","article-title":"Profibrotic, electrical, and calcium-handling remodeling of the atria in heart failure patients with and without atrial fibrillation","volume":"9","author":"Molina","year":"2018","journal-title":"Front. Physiol."},{"issue":"26","key":"10.1016\/j.ijcha.2020.100573_b0110","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.2174\/1381612824666180903125300","article-title":"Mitochondria and the pathophysiological mechanism of atrial fibrillation","volume":"24","author":"Li","year":"2018","journal-title":"Curr. Pharm. Des."},{"issue":"8","key":"10.1016\/j.ijcha.2020.100573_b0115","first-page":"1555","article-title":"Redox control of cardiac remodeling in atrial fibrillation","volume":"1850","author":"Wolke","year":"2015","journal-title":"BBA"},{"issue":"20","key":"10.1016\/j.ijcha.2020.100573_b0120","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1161\/CIRCULATIONAHA.118.035202","article-title":"Enhanced cardiomyocyte NLRP3 inflammasome signaling promotes atrial fibrillation","volume":"138","author":"Yao","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ijcha.2020.100573_b0125","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ijcard.2018.10.020","article-title":"Role of inflammatory signaling in atrial fibrillation","volume":"287","author":"Scott","year":"2019","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcha.2020.100573_b0130","first-page":"11","article-title":"Antiarrhythmic drugs for atrial fibrillation: Imminent impulses are emerging","volume":"21","author":"Dan","year":"2018","journal-title":"Int. J. Cardiol. Heart Vasc."},{"key":"10.1016\/j.ijcha.2020.100573_b0135","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.pharmthera.2017.10.016","article-title":"Therapeutic potential of omega-3 fatty acid-derived epoxyeicosanoids in cardiovascular and inflammatory diseases","volume":"183","author":"Schunck","year":"2018","journal-title":"Pharmacol. Ther."},{"issue":"43","key":"10.1016\/j.ijcha.2020.100573_b0140","doi-asserted-by":"crossref","first-page":"32720","DOI":"10.1074\/jbc.M110.118406","article-title":"Arachidonic acid-metabolizing cytochrome P450 enzymes are targets of omega-3 fatty acids","volume":"285","author":"Arnold","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.ijcha.2020.100573_b0145","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1194\/jlr.M047357","article-title":"Dietary omega-3 fatty acids modulate the eicosanoid profile in man primarily via the CYP-epoxygenase pathway","volume":"55","author":"Fischer","year":"2014","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ijcha.2020.100573_b0150","doi-asserted-by":"crossref","unstructured":"V. Samokhvalov, K.L. Jamieson, J. Vriend, S. Quan, J.M. Seubert, CYP-epoxygenase metabolites of docosahexaenoic acid protect HL-1 cardiac cells against LPS-induced cytotoxicity Through SIRT1, Cell Death Discov. (2015) 1.","DOI":"10.1038\/cddiscovery.2015.54"},{"key":"10.1016\/j.ijcha.2020.100573_b0155","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3389\/fphar.2016.00124","article-title":"SIRT is required for EDP-mediated protective responses toward hypoxia-reoxygenation injury in cardiac cells","volume":"7","author":"Samokhvalov","year":"2016","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ijcha.2020.100573_b0160","first-page":"1","article-title":"Cardioprotective effects of CYP-derived epoxy metabolites of docosahexaenoic acid involve limiting NLRP3 inflammasome activation (1)","author":"Darwesh","year":"2018","journal-title":"Can. J. Physiol. Pharmacol."},{"issue":"1\u20134","key":"10.1016\/j.ijcha.2020.100573_b0165","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.prostaglandins.2011.09.001","article-title":"CYP-eicosanoids\u2013a new link between omega-3 fatty acids and cardiac disease?","volume":"96","author":"Westphal","year":"2011","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"10.1016\/j.ijcha.2020.100573_b0170","doi-asserted-by":"crossref","unstructured":"P. Sirish, N. Li, V. Timofeyev, X.D. Zhang, L. Wang, J. Yang, et al., Molecular mechanisms and new treatment paradigm for atrial fibrillation, Circul. Arrhythmia Electrophysiol. 9(5) (2016).","DOI":"10.1161\/CIRCEP.115.003721"},{"issue":"8","key":"10.1016\/j.ijcha.2020.100573_b0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0073490","article-title":"CYP2J2 overexpression protects against arrhythmia susceptibility in cardiac hypertrophy","volume":"8","author":"Westphal","year":"2013","journal-title":"PLoS ONE"},{"issue":"49","key":"10.1016\/j.ijcha.2020.100573_b0180","doi-asserted-by":"crossref","first-page":"18733","DOI":"10.1073\/pnas.0609158103","article-title":"Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors","volume":"103","author":"Xu","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ijcha.2020.100573_b0185","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1136\/gut.2005.080754","article-title":"Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin nonsteroidal anti-inflammatory drugs, aspirin and combinations","volume":"55","author":"Lanas","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.ijcha.2020.100573_b0190","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/archinternmed.2010.271","article-title":"Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation","volume":"170","author":"Hansen","year":"2010","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.ijcha.2020.100573_b0195","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.amjmed.2015.12.026","article-title":"Triple vs dual antithrombotic therapy in patients with atrial fibrillation and coronary artery disease","volume":"129","author":"Lopes","year":"2016","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ijcha.2020.100573_b0200","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1016\/S0140-6736(09)61751-7","article-title":"Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data","volume":"374","author":"S\u00f8rensen","year":"2009","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ijcha.2020.100573_b0205","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.hrthm.2015.01.021","article-title":"Ranolazine in the treatment of atrial fibrillation: results of the dose-ranging RAFFAELLO (Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion) study","volume":"12","author":"De Ferrari","year":"2015","journal-title":"Heart Rhythm"},{"issue":"25","key":"10.1016\/j.ijcha.2020.100573_b0210","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1016\/j.jacc.2014.04.019","article-title":"Clinical classifications of atrial fibrillation poorly reflect its temporal persistence","volume":"63","author":"Charitos","year":"2014","journal-title":"JACC"}],"container-title":["IJC Heart & Vasculature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352906720302712?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352906720302712?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T05:08:29Z","timestamp":1762492109000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352906720302712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":42,"alternative-id":["S2352906720302712"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcha.2020.100573","relation":{},"ISSN":["2352-9067"],"issn-type":[{"type":"print","value":"2352-9067"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of OMT-28, a synthetic analog of omega-3 epoxyeicosanoids, in patients with persistent atrial fibrillation: Rationale and design of the PROMISE-AF phase II study","name":"articletitle","label":"Article Title"},{"value":"IJC Heart & Vasculature","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcha.2020.100573","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100573"}}